Aligos Therapeutics (ALGS) Tax Provisions (2020 - 2026)

Aligos Therapeutics (ALGS) has reported Tax Provisions for 7 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions rose 1419.46% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at -$2.1 million (down 711.27% YoY), and the FY2025 full-year result was -$5.0 million, down 1615.11% from the prior year.
• Tax Provisions climbed to $2.8 million in Q2 2026 per ALGS's latest filing, from $317000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $2.8 million in Q2 2026 and bottomed at -$5.3 million in Q4 2025.
• Historically, Tax Provisions has averaged -$36388.9 across 5 years, with a median of $48000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Tax Provisions jumped 1510.64% in 2023, then plunged 19725.93% in 2025.
• Over 5 years, Tax Provisions stood at $49000.0 in 2022, then slumped by 161.22% to -$30000.0 in 2023, then jumped by 190.0% to $27000.0 in 2024, then slumped by 19725.93% to -$5.3 million in 2025, then jumped by 153.05% to $2.8 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $2.8 million, $317000.0, and -$5.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.